{
    "NCT06566170": {
        "inclusion": {
            "1": [
                "The patient is under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD, as indicated by progressive memory loss and severe cognitive deficits. This criterion is applicable.",
                [
                    1,
                    2
                ],
                "included"
            ],
            "2": [
                "The patient note does not provide a TICS score. It is not possible to infer this information from the provided details. Therefore, there is not enough information.",
                [],
                "not enough information"
            ],
            "3": [
                "The patient note does not mention any amyloid beta (A\u03b2) pathology biomarkers such as P-tau, amyloid PET, or CSF. It is not possible to infer this information from the provided details. Therefore, there is not enough information.",
                [],
                "not enough information"
            ],
            "4": [
                "The patient note does not mention the presence of a reliable study partner. It is not possible to infer this information from the provided details. Therefore, there is not enough information.",
                [],
                "not enough information"
            ],
            "5": [
                "The patient note does not mention the availability of EHR data or willingness to allow access. It is not possible to infer this information from the provided details. Therefore, there is not enough information.",
                [],
                "not enough information"
            ]
        },
        "inclusion_criteria": [
            "1. are under care for presumed mild cognitive impairment (MCI) or mild dementia stage of AD (Note: neither a biomarker-based diagnosis of AD nor a diagnosis in electronic health records \\[EHR\\] is required prior to screening)",
            "2. have a Telephone Interview for Cognitive Status (TICS) score of \u226521",
            "3. presence of amyloid beta (A\u03b2) pathology supported by biomarker results (e.g., P-tau, amyloid positron emission tomography (PET), and/or cerebrospinal fluid \\[CSF\\]). (Note: A historical biomarker may be used for eligibility if performed within 12 months of study entry)",
            "4. have a reliable study partner who is in frequent contact with the participant and will be available by telephone at designated times (every 6 months), and",
            "5. have EHR data available for linkage and are willing to allow access to EHR data for the duration of the study."
        ],
        "exclusion": {
            "1": [
                "The patient does not have a history of ischemic or hemorrhagic stroke, nor is there any mention of an inability to independently perform basic activities of daily living (ADLs).",
                [],
                "not applicable"
            ],
            "2": [
                "There is no mention of serious or unstable illness other than Alzheimer's Disease in the patient's note.",
                [],
                "not excluded"
            ],
            "3": [
                "There is no mention of the patient being enrolled or intending to enroll in another clinical trial.",
                [],
                "not excluded"
            ],
            "4": [
                "The patient does not have any contraindications to donanemab, MRI, or amyloid PET tracers mentioned in the note.",
                [],
                "not excluded"
            ]
        },
        "exclusion_criteria": [
            "1. have prior ischemic or hemorrhagic stroke(s) with an inability to independently perform any one or more basic activities of daily living (ADLs) (i.e., walking, transferring, eating, bathing, dressing, or toileting). (Note: mixed dementias with amyloid pathology are permitted)",
            "2. have current or recent serious or unstable illness (other than AD) that, in the investigator's opinion, could interfere with the ability of the participant or study partner to complete the study (e.g., life expectancy of less than 36 months, requirement for long-term (\\>12 months) institutional-level care, serious psychiatric illness, etc.)",
            "3. are currently enrolled or intend to enroll in a clinical trial of another investigational product, and",
            "4. have contraindications to donanemab, magnetic resonance imaging (MRI), or amyloid PET tracers. (Donanemab group only)."
        ]
    },
    "NCT06657768": {
        "inclusion": "{\n  \"1\": [\"The patient is a 62-year-old man with progressive memory loss and cognitive deficits, which are symptoms of Alzheimer's Disease. The EEG and neuroimaging studies support the diagnosis of Alzheimer's Disease. The cortical biopsy shows changes consistent with Alzheimer's Disease. The patient does not meet the inclusion criteria because the patient has Alzheimer's Disease, not a healthy state. [], \"not applicable\"],\n  \"2\": [\"The patient has progressive memory loss and cognitive deficits, which are symptoms of Alzheimer's Disease. The EEG and neuroimaging studies support the diagnosis of Alzheimer's Disease. The cortical biopsy shows changes consistent with Alzheimer's Disease. The patient does not meet the inclusion criteria because the patient has Alzheimer's Disease, not early symptomatic Alzheimer's Disease. [], \"not included\"]\n}",
        "exclusion": {
            "1": [
                "The patient has progressive memory loss and jerking movements, which indicates a diagnosis of a neurological condition, not a healthy participant. The study is for early symptomatic Alzheimer's Disease (AD), and the patient's symptoms do not align with this. Therefore, the criterion is not applicable.",
                [],
                "not applicable"
            ],
            "2": [
                "The patient has severe cognitive deficits and memory dysfunction, which are symptoms of Alzheimer's Disease, not a healthy participant. The study is for early symptomatic Alzheimer's Disease (AD), and the patient's symptoms do not align with this. Therefore, the criterion is not applicable.",
                [],
                "not applicable"
            ],
            "3": [
                "The patient has generalized periodic sharp waves on an electroencephalogram, moderately advanced cerebral atrophy on neuroimaging, and diffuse vacuolar changes on cortical biopsy, all indicative of Alzheimer's Disease. The study is for early symptomatic Alzheimer's Disease (AD), and the patient's symptoms do not align with this. Therefore, the criterion is not applicable.",
                [],
                "not applicable"
            ],
            "4": [
                "The patient's compliance with the trial protocol is assured, but the study is for early symptomatic Alzheimer's Disease (AD), and the patient's symptoms do not align with this. Therefore, the criterion is not applicable.",
                [],
                "not applicable"
            ]
        },
        "exclusion_criteria": []
    },
    "NCT06653153": {
        "inclusion": {
            "1": [
                "The patient note does not mention phosphorylated tau (P-tau) results. It is possible that a good patient note could miss such information, but it is crucial for diagnosis in this study.",
                [],
                "not enough information"
            ],
            "2": [
                "The patient note does not mention the presence of a reliable study partner and backup study partner familiar with the patient's function and behavior.",
                [],
                "not enough information"
            ],
            "3": [
                "The patient note does not provide information about the patient's literacy, vision, or hearing.",
                [],
                "not enough information"
            ],
            "4": [
                "The patient note does not provide a Mini Mental Status Exam (MMSE) score.",
                [],
                "not enough information"
            ],
            "5": [
                "The patient note does not provide a Functional Activities Questionnaire (FAQ) score.",
                [],
                "not enough information"
            ],
            "6": [
                "The patient note does not mention if the patient is currently receiving medications for Alzheimer's disease or if the dose has been stable for at least 30 days before screening.",
                [],
                "not enough information"
            ]
        },
        "inclusion_criteria": [
            "1. Have a phosphorylated tau (P-tau) result consistent with the presence of amyloid pathology.",
            "2. Have a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.",
            "3. Have adequate literacy, vision, and hearing for neuropsychological testing at screening.",
            "4. Have a Mini Mental Status Exam (MMSE) score consistent with no to minimal cognitive impairment.",
            "5. Have a Functional Activities Questionnaire (FAQ) score consistent with no to minimal functional impairment.",
            "6. If currently receiving medications as symptomatic treatment for AD, dose has been stable for at least 30 days before screening."
        ],
        "exclusion": {
            "1": [
                "The patient has progressive memory loss and jerking movements, which could indicate dementia or significant neurological disease. However, the diagnosis is not explicitly stated as Alzheimer's Disease, which is the specific target of this study. The note does not provide enough information to confirm the presence of dementia or significant other neurological disease.",
                [],
                "not enough information"
            ],
            "2": [
                "The patient note does not mention any serious or unstable illnesses that could interfere with the study.",
                [],
                "not excluded"
            ],
            "3": [
                "The patient note does not mention any history of cancer.",
                [],
                "not excluded"
            ],
            "4": [
                "The patient note does not mention any history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.",
                [],
                "not excluded"
            ],
            "5": [
                "The patient note does not mention any clinically important laboratory test results or other abnormalities.",
                [],
                "not enough information"
            ],
            "6": [
                "The patient note does not mention any contraindications for MRI.",
                [],
                "not excluded"
            ],
            "7": [
                "The patient note does not mention any centrally read MRI results.",
                [],
                "not enough information"
            ],
            "8": [
                "The patient note does not mention any prior or current therapies.",
                [],
                "not enough information"
            ],
            "9": [
                "The patient note does not mention any prior treatment with passive anti-amyloid immunotherapy.",
                [],
                "not excluded"
            ],
            "10": [
                "The patient note does not mention any active immunization against A\u03b2 in any other study.",
                [],
                "not excluded"
            ]
        },
        "exclusion_criteria": [
            "1. Have dementia or significant other neurological disease that can affect cognition.",
            "2. Have current serious or unstable illnesses that in the investigator's opinion, could interfere with the analyses of the study.",
            "3. Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence.",
            "4. Have a history of clinically significant multiple or severe drug allergies, or hypersensitivity reactions.",
            "5. Have a clinically important laboratory test result or other abnormality as determined by investigator, prior to randomization, that could be detrimental to the participant or could compromise the study.",
            "6. Have any contraindications for magnetic resonance imaging (MRI).",
            "7. Have a centrally read MRI that does not meets study entry criteria.",
            "8. Prior or Current Therapies",
            "9. Have ever had prior treatment with a passive anti-amyloid immunotherapy.",
            "10. Have received active immunization against A\u03b2 in any other study."
        ]
    },
    "NCT06220669": {
        "inclusion": {
            "1": [
                "The criterion is not applicable because the patient note describes progressive memory loss and jerking movements, which are not symptoms of relapsing multiple sclerosis (RMS). The note does not mention multiple sclerosis or any relapsing course.",
                [],
                "not applicable"
            ],
            "2": [
                "The criterion is not applicable because the patient note does not mention multiple sclerosis at all.",
                [],
                "not applicable"
            ],
            "3": [
                "The criterion is not applicable because the patient note does not mention any documented relapses.",
                [],
                "not applicable"
            ],
            "4": [
                "The criterion is not applicable because the patient note does not mention any documented relapses.",
                [],
                "not applicable"
            ],
            "5": [
                "The criterion is not applicable because the patient note does not mention any GdE brain lesions.",
                [],
                "not applicable"
            ],
            "6": [
                "The criterion is not applicable because the patient note does not mention any EDSS scores.",
                [],
                "not applicable"
            ]
        },
        "inclusion_criteria": [
            "1. Participants must meet criteria for relapsing forms of multiple sclerosis, including relapsing-remitting multiple sclerosis based on the 2017 revision of the McDonald diagnostic criteria (Thompson et al. 2018) with a relapsing course (RMS) activity according to Klineova and Lublin 2018.",
            "2. Participants must have 1 of these:",
            "3. at least 1 documented relapse within the previous year",
            "4. at least 2 documented relapses within the previous 2 years, or",
            "5. at least 1 active GdE brain lesion on an MRI scan in the past 180 days prior to screening.",
            "6. Have an Expanded Disability Status Scale (EDSS) score of less than or equal to (\u2264) 5.5 at screening and randomization."
        ],
        "exclusion": {
            "1": [
                "The patient note does not mention primary progressive MS or nonactive secondary progressive MS, and there is no evidence of neuromyelitis optica spectrum disorder. It is not possible to infer these conditions from the provided information.",
                [],
                "not applicable"
            ],
            "2": [
                "The patient note does not mention primary progressive MS or nonactive secondary progressive MS, and there is no evidence of neuromyelitis optica spectrum disorder. It is not possible to infer these conditions from the provided information.",
                [],
                "not applicable"
            ],
            "3": [
                "The patient note does not mention neuromyelitis optica spectrum disorder. It is not possible to infer this condition from the provided information.",
                [],
                "not excluded"
            ],
            "4": [
                "The patient note describes cerebral atrophy and generalized periodic sharp waves, but does not mention any other clinically significant CNS disease. It is not possible to infer other CNS diseases from the provided information.",
                [],
                "not excluded"
            ],
            "5": [
                "The patient note does not mention any recent relapses or systemic corticosteroid administration. It is not possible to infer this information from the provided details.",
                [],
                "not excluded"
            ],
            "6": [
                "The patient note does not mention any MRI scans or details about active GdE brain lesions. It is not possible to infer this information from the provided details.",
                [],
                "not enough information"
            ],
            "7": [
                "The patient note does not mention any specific medications or treatments received. It is not possible to infer this information from the provided details.",
                [],
                "not enough information"
            ],
            "8": [
                "The patient note does not mention any current or recent acute, active infections. It is not possible to infer this information from the provided details.",
                [],
                "not excluded"
            ],
            "9": [
                "The patient note does not mention any current serious or unstable illnesses. It is not possible to infer this information from the provided details.",
                [],
                "not excluded"
            ],
            "10": [
                "The patient note does not mention any other clinically important abnormalities at screening or baseline. It is not possible to infer this information from the provided details.",
                [],
                "not excluded"
            ]
        },
        "exclusion_criteria": [
            "1. primary progressive multiple sclerosis (MS) according to the 2017 revision of McDonald diagnostic criteria (Thompson et al. 2018), or",
            "2. nonactive secondary progressive MS ( Klineova and Lublin 2018).",
            "3. Meet criteria for neuromyelitis optica spectrum disorder (Wingerchuk and Lucchinetti 2022).",
            "4. Have a history of clinically significant central nervous system (CNS) disease.",
            "5. Have had a confirmed relapse with systemic corticosteroid administration \\<30 days prior to randomization.",
            "6. Have more than 20 active GdE brain lesions on screening MRI scan.",
            "7. Have received any of these medications or treatments.",
            "8. Have a current or recent acute, active infection.",
            "9. Have current serious or unstable illnesses.",
            "10. Have any other clinically important abnormality at screening or baseline."
        ]
    },
    "NCT05026866": {
        "inclusion": {
            "1": [
                "The patient does not meet the criterion as they have severe cognitive deficits and memory dysfunction, which indicates impaired cognitive functioning. Therefore, the criterion is not applicable.",
                [],
                "not applicable"
            ],
            "2": [
                "The patient note does not mention any details about phosphorylated tau (P-tau) results. It is impossible to determine if the patient's P-tau result is consistent with the presence of amyloid and early-tau pathology.",
                [],
                "not enough information"
            ],
            "3": [
                "The patient note does not mention any information about a study partner or backup study partner familiar with the patient's overall function and behavior.",
                [],
                "not enough information"
            ],
            "4": [
                "The patient note does not mention any details about the patient's literacy, vision, or hearing. It is impossible to determine if the patient has adequate literacy, vision, and hearing for neuropsychological testing.",
                [],
                "not enough information"
            ],
            "5": [
                "The patient note does not mention any details about contraceptive use by the patient. This criterion is not applicable to the patient as it is a male.",
                [],
                "not applicable"
            ],
            "6": [
                "The patient note does not mention any details about the female participants' reproductive status. This criterion is not applicable to the patient as it is a male.",
                [],
                "not applicable"
            ]
        },
        "inclusion_criteria": [
            "1. A Telephone Interview for Cognitive Status - modified (TICS-M) score reflective of intact cognitive functioning.",
            "2. Has a phosphorylated tau (P-tau) result consistent with the presence of amyloid and early-tau pathology.",
            "3. Has a reliable study partner and backup study partner familiar with overall function and behavior, such as day-to-day activities and cognitive abilities.",
            "4. Have adequate literacy, vision, and hearing for neuropsychological testing at screening.",
            "5. Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies",
            "6. Female participants include those who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as Mullerian agenesis; or post menopausal (women 55 or older not on hormone therapy and had at least 12 months of spontaneous amenorrhea; or with a diagnosis of menopause prior to starting hormone replacement therapy."
        ],
        "exclusion": {
            "1": [
                "The patient has severe cognitive deficits and memory dysfunction, which indicates significant other neurodegenerative disease affecting cognition, thus meeting the exclusion criterion.",
                [
                    2
                ],
                "excluded"
            ],
            "2": [
                "The patient's condition does not mention any serious or unstable illnesses that could interfere with the study or have a life expectancy of \u22645 years.",
                [],
                "not enough information"
            ],
            "3": [
                "No history of cancer is mentioned in the note.",
                [],
                "not excluded"
            ],
            "4": [
                "No history of clinically significant multiple or severe drug allergies is mentioned in the note.",
                [],
                "not enough information"
            ],
            "5": [
                "No clinically important abnormalities on MRI or laboratory tests are mentioned in the note.",
                [],
                "not enough information"
            ],
            "6": [
                "No contraindications for MRI are mentioned in the note.",
                [],
                "not excluded"
            ],
            "7": [
                "No MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), cerebral microhemorrhages, superficial siderosis, macrohemorrhage, or severe white matter disease is mentioned in the note.",
                [],
                "not enough information"
            ],
            "8": [
                "No prior treatment with passive anti-amyloid immunotherapy is mentioned in the note.",
                [],
                "not excluded"
            ],
            "9": [
                "No previous active immunization against amyloid beta (A\u03b2) in any other study is mentioned in the note.",
                [],
                "not excluded"
            ],
            "10": [
                "This criterion is a duplicate of criterion 9.",
                [],
                "not applicable"
            ],
            "11": [
                "No current or previous use of prescription medications for mild cognitive impairment (MCI) or AD is mentioned.",
                [],
                "not excluded"
            ],
            "12": [
                "Same as main study criteria, no contraindications for florbetapir F 18 PET are mentioned.",
                [],
                "not excluded"
            ]
        },
        "exclusion_criteria": [
            "1. Mild cognitive impairment or dementia, or significant other neurodegenerative disease that can affect cognition.",
            "2. Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic, psychiatric, immunologic, or hematologic disease that could interfere with the analysis of the study or a life expectancy of approximately \u22645 years.",
            "3. History of cancer with high risk of recurrence and preventing completion of the trial.",
            "4. History of clinically significant multiple or severe drug allergies, or severe posttreatment hypersensitivity reactions (including but not limited to erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfoliative dermatitis).",
            "5. Have any clinically important abnormality at screening on magnetic resonance imaging (MRI) or clinical laboratory test results that could be detrimental to the participant or study integrity.",
            "6. Have any contraindications for MRI, including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.",
            "7. Have a centrally read MRI demonstrating presence of amyloid-related imaging abnormalities (ARIA-E), \\>4 cerebral microhemorrhages, more than 1 area of superficial siderosis, any macrohemorrhage or severe white matter disease at screening.",
            "8. Have had prior treatment with a passive anti-amyloid immunotherapy \\<5 half-lives prior to randomization.",
            "9. Have received active immunization against amyloid beta (A\u03b2) in any other study.",
            "10. Have received active immunization against A\u03b2 in any other study.",
            "11. Current or previous use of prescription medications used as treatment for mild cognitive impairment (MCI) or AD.",
            "12. Same as the main study except contraindications for florbetapir F 18 PET are exclusionary."
        ]
    },
    "NCT05508789": {
        "inclusion": {
            "1": [
                "The patient reports progressive memory loss, which is gradual and progressive for at least 6 months, but the exact duration is not specified. It is possible that the patient's memory loss has been gradual and progressive for more than 6 months, but the note does not provide explicit evidence of this duration. Therefore, it is not possible to definitively determine if the criterion is met without additional information.",
                [],
                "not enough information"
            ],
            "2": [
                "The patient's MMSE score range is not provided in the note. The MMSE score of 20 to 28 (inclusive) is required for eligibility, but there is no direct evidence of the MMSE score in the patient note.",
                [],
                "not enough information"
            ],
            "3": [
                "There is no mention of flortaucipir F18 scan results in the patient note.",
                [],
                "not enough information"
            ],
            "4": [
                "There is no mention of florbetapir F18 scan results in the patient note.",
                [],
                "not enough information"
            ],
            "5": [
                "The patient note does not mention a study partner or any information about a study partner's availability or consent.",
                [],
                "not enough information"
            ],
            "6": [
                "The patient note does not mention a second study partner or any information about a second study partner.",
                [],
                "not enough information"
            ],
            "7": [
                "The patient note does not mention any information about a second study partner being primarily responsible for the CDR and the ADCS-ADL assessments.",
                [],
                "not enough information"
            ],
            "8": [
                "The patient note does not mention any information about the availability of a study partner by telephone for AEs and concomitant medications.",
                [],
                "not enough information"
            ],
            "9": [
                "The patient note does not mention any information about stable concomitant symptomatic AD medications or other medications that may impact cognition for at least 30 days prior to randomization.",
                [],
                "not enough information"
            ]
        },
        "inclusion_criteria": [
            "1. Gradual and progressive change in memory function reported by the participant or informant for \u22656 months",
            "2. A MMSE score of 20 to 28 (inclusive) at Day 601 or 1.",
            "3. Meet flortaucipir F18 scan (central read) criteria",
            "4. Meet florbetapir F18 scan (central read) criteria",
            "5. Have a study partner who will provide written informed consent to participate, is in frequent contact with the participant (defined as at least 10 hours per week), and will accompany the participant to the study or be available by telephone at designated times.",
            "6. A second study partner may serve as backup. The study partner(s) is/are required to accompany the participant for signing consent. The study partner must be present on all days the cognitive and functional scales are administered.",
            "7. If a participant has a second study partner, it is preferred that 1 study partner be primarily responsible for the CDR and the ADCS-ADL assessments.",
            "8. Days requiring the following assessments and scales must have a study partner available by telephone if not accompanying participant for the following assessments",
            "9. AEs and concomitant medications",
            "10. Stable concomitant symptomatic AD medications and other medications that may impact cognition for at least approximately 30 days prior to randomization."
        ],
        "exclusion": {
            "1": [
                "The patient has progressive memory loss and jerking movements, but no mention of other significant neurological diseases affecting the central nervous system other than AD. The note does not provide direct evidence of other neurological diseases, but the absence of such information does not necessarily mean they do not exist. Therefore, there is not enough information.",
                [],
                "not enough information"
            ],
            "2": [
                "The patient's note does not mention any current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, psychiatric, immunologic, or hematologic diseases. There is no direct evidence, but the absence of such information implies these conditions are not present. The note also does not mention a life expectancy of less than 24 months.",
                [],
                "not excluded"
            ],
            "3": [
                "The patient's note does not mention any history of cancer within the last 5 years, except for non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with low risk of recurrence or spread. There is no direct evidence, but the absence of such information implies these conditions are not present.",
                [],
                "not excluded"
            ],
            "4": [
                "The patient's note does not mention any contraindication to MRI or PET scans.",
                [],
                "not excluded"
            ]
        },
        "exclusion_criteria": [
            "1. Has significant neurological disease affect the central nervous system other than AD, that may affect cognition or ability to complete the study, including but not limited to, other dementias, serious infection of the brain, Parkinson's disease, multiple concussions, or epilepsy or recurrent seizures (except febrile childhood seizures).",
            "2. Has current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of \\<24 months.",
            "3. History of cancer within the last 5 years, except of non-metastatic basal and/or squamous cell carcinoma of the skin, in situ cervical cancer, nonprogressive prostate cancer, or other cancers with low risk of recurrence or spread.",
            "4. Contraindication to MRI or PET scans"
        ]
    },
    "NCT06809400": {
        "inclusion": {
            "1": [
                "The patient is a 62-year-old man, which falls within the typical age range for Parkinson's Disease. There is no direct evidence of BMI, but no exclusion based on age. Relevant sentence IDs: [1], Eligibility label: included"
            ],
            "2": [
                "The patient's BMI is not mentioned in the note. It is impossible to determine if the patient's BMI is within the specified range without this information. Relevant sentence IDs: [], Eligibility label: not enough information"
            ],
            "3": [
                "Not applicable as the patient is not Japanese. Relevant sentence IDs: [], Eligibility label: not applicable"
            ],
            "4": [
                "The patient has venous access as implied by the ability to provide informed consent and comply with the protocol, which includes blood sampling. Relevant sentence IDs: [6], Eligibility label: included"
            ],
            "5": [
                "Not applicable as the patient is not Chinese. Relevant sentence IDs: [], Eligibility label: not applicable"
            ],
            "6": [
                "The patient shows symptoms consistent with Parkinson's Disease: progressive memory loss, cognitive deficits, memory dysfunction, and jerking movements. Relevant sentence IDs: [1, 2], Eligibility label: included"
            ],
            "7": [
                "The patient's treatment status is not mentioned, but there is no indication that the disease is expected to require changes in treatment within 52 weeks. Relevant sentence IDs: [], Eligibility label: included"
            ],
            "8": [
                "The patient's treatment status is not mentioned, but there is no indication that the patient is currently on dopaminergic therapy. Relevant sentence IDs: [], Eligibility label: not applicable"
            ],
            "9": [
                "The patient's cognitive assessment score is not mentioned in the note. It is impossible to determine if the patient's MoCA score is within the specified range without this information. Relevant sentence IDs: [], Eligibility label: not enough information"
            ]
        },
        "inclusion_criteria": [
            "1. Part A Single Ascending Dose (SAD) and B Multiple Ascending Dose (MAD)",
            "2. Have a body mass index within the range of 18 to 34 kilogram/square meter (kg/m\u00b2) (inclusive).",
            "3. For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.",
            "4. Have venous access sufficient to allow for blood sampling or administration of study intervention for IV administration, or both.",
            "5. For Chinese participants: To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be exclusive Chinese descent and born in China.",
            "6. Diagnosis of Parkinson's disease per United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.",
            "7. If presently untreated for Parkinson's disease, clinical status is not expected to require changes in symptomatic treatment within 52 weeks from baseline.",
            "8. If presently being treated for Parkinson's disease, receiving a stable dose of symptomatic dopaminergic therapy, including monoamine oxidase-B inhibitor, levodopa/carbidopa or dopamine agonist for at least 90 days prior to baseline and not expected to change within 52 weeks.",
            "9. Have a Montreal Cognitive Assessment (MoCA) score of greater than or equal to (\u2265) 26."
        ],
        "exclusion": {
            "1": [
                "The criterion specifies significant neurological disease other than Parkinson's disease. The patient note describes progressive memory loss, jerking movements, cognitive deficits, and cerebral atrophy, indicating significant neurological disease. Therefore, the patient meets the criterion. Relevant information is present in the note.",
                [
                    1,
                    2,
                    3,
                    4,
                    5
                ],
                "excluded"
            ],
            "2": [
                "The criterion involves the presence of serious or unstable illnesses that could interfere with the study or reduce life expectancy to less than 24 months. The note does not mention any serious or unstable illnesses or conditions, but it does describe significant neurological disease. Given the severity of the patient's condition, it is likely that such conditions could be inferred if present. However, there is no direct evidence.",
                [],
                "not enough information"
            ],
            "3": [
                "The criterion involves known allergies to LY4006896 or related compounds. The note does not mention any allergies to LY4006896 or related compounds. Given the specificity of the criterion, it is unlikely that such information would be missed if present.",
                [],
                "not excluded"
            ],
            "4": [
                "The criterion involves significant allergies to humanize monoclonal antibodies. The note does not mention any allergies to humanize monoclonal antibodies. Given the specificity of the criterion, it is unlikely that such information would be missed if present.",
                [],
                "not excluded"
            ],
            "5": [
                "The criterion involves clinically significant multiple or severe drug allergies or severe posttreatment hypersensitivity reactions. The note does not mention any such allergies. Given the specificity of the criterion, it is unlikely that such information would be missed if present.",
                [],
                "not excluded"
            ],
            "6": [
                "The criterion involves history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or common variable immune deficiency. The note does not mention any of these conditions. Given the specificity of the criterion, it is unlikely that such information would be missed if present.",
                [],
                "not excluded"
            ],
            "7": [
                "The criterion involves evidence of clinically significant anemia. The note does not mention any anemia. Given the specificity of the criterion, it is unlikely that such information would be missed if present.",
                [],
                "not excluded"
            ],
            "8": [
                "The criterion involves abnormal blood pressure or pulse rate, or both, or preexisting hypertension. The note does not mention any abnormalities in blood pressure or pulse rate. Given the specificity of the criterion, it is unlikely that such information would be missed if present.",
                [],
                "not excluded"
            ],
            "9": [
                "The criterion involves uncontrolled hypertension with systolic blood pressure >150 mm Hg or diastolic blood pressure >95 mm Hg. The note does not mention any blood pressure readings. Given the specificity of the criterion, it is unlikely that such information would be missed if present.",
                [],
                "not excluded"
            ]
        },
        "exclusion_criteria": [
            "1. Have significant neurological disease affecting the central nervous system (CNS) (other than Parkinson's disease in Part B cohorts) that may affect the participant's ability to complete the study.",
            "2. Have a history or presence of serious or unstable illnesses or conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than 24 months.",
            "3. Have known allergies to LY4006896, related compounds, or any components of the formulation, or history of allergic reactions to any transferrin receptor antibodies.",
            "4. Have significant allergies to humanize monoclonal antibodies.",
            "5. Have clinically significant multiple or severe drug allergies (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis); or intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions.",
            "6. Have history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency.",
            "7. Evidence of clinically significant anemia.",
            "8. Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension.",
            "9. Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure \\>150 mm Hg or a diastolic blood pressure \\>95 mm Hg at Screening or Treatment Visits."
        ]
    },
    "NCT06538116": {
        "inclusion": {
            "1": [
                "The patient does not have a clear mention of a gradual and progressive decline in memory function for greater than or equal to 6 months. The note mentions progressive memory loss but does not specify the duration of progression. It is possible that a good patient note could miss such specific duration information.",
                [],
                "not enough information"
            ],
            "2": [
                "The patient note does not mention an MMSE score. It is possible that a good patient note could miss such specific information.",
                [],
                "not enough information"
            ],
            "3": [
                "The patient note does not mention plasma P-tau levels or historical evidence of AD pathology. It is possible that a good patient note could miss such specific information.",
                [],
                "not enough information"
            ],
            "4": [
                "The patient note mentions that the patient will comply with the trial protocol and does not mention the absence of a reliable study partner. It is unlikely that a good patient note would miss the presence of a reliable study partner.",
                [
                    "6"
                ],
                "included"
            ],
            "5": [
                "The patient note does not provide information about whether the patient is male and has a partner of childbearing potential, nor does it mention any contraception guidance. It is possible that a good patient note could miss such specific information.",
                [],
                "not enough information"
            ]
        },
        "inclusion_criteria": [
            "1. Have gradual and progressive decline in memory function for greater than or equal to 6 months that is severe enough to interfere with activities of daily living.",
            "2. Have MMSE score of 13 to 24.",
            "3. Have eligibile plasma P-tau or historical evidence of AD pathology.",
            "4. Have a reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant and will be available at designated times.",
            "5. Males with partners of childbearing potential must agree to abide with provided contraception guidance."
        ],
        "exclusion": {
            "1": [
                "The criterion is not applicable as the patient is male and the study is for individuals of childbearing potential, which typically refers to females. The patient note does not mention any female-specific conditions or reproductive status.",
                [],
                "not applicable"
            ],
            "2": [
                "The patient has no mention of other significant central nervous system or psychiatric diseases apart from the diagnosis of Alzheimer's Disease. The note does not indicate any head trauma, stroke, seizure disorder, etc.",
                [
                    1,
                    2,
                    3,
                    4,
                    5,
                    6
                ],
                "not excluded"
            ],
            "3": [
                "The patient note does not mention any cardiovascular-related risk factors or history such as uncontrolled hypertension, heart failure, stroke, or liver-related abnormalities.",
                [],
                "not excluded"
            ],
            "4": [
                "There is no mention of the use of CYP3A4 inhibitors or inducers in the patient note.",
                [],
                "not excluded"
            ],
            "5": [
                "The patient note does not mention any participation in a clinical trial involving an investigational product within the last 30 days.",
                [],
                "not excluded"
            ],
            "6": [
                "There is no mention of suicidal tendencies or risk in the patient note.",
                [],
                "not excluded"
            ]
        },
        "exclusion_criteria": [
            "1. Are individuals of childbearing potential.",
            "2. Have significant central nervous system or psychiatric disease, other than AD, that in the investigator's opinion may affect cognition or the ability to complete the study (e.g: head trauma, stroke, seizure disorder etc.,).",
            "3. Have cardiovascular-related risk factors or history that include uncontrolled hypertension, heart failure, stroke; or liver-related abnormalities.",
            "4. Use of moderate or strong CYP3A4 inhibitors or inducers.",
            "5. Have participated within the last 30 days in a clinical trial involving an investigational product.",
            "6. Participant is, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide."
        ]
    },
    "NCT06297590": {
        "inclusion": {
            "1": [
                "The patient's age is not mentioned in the BMI range, but the patient is 62 years old, which is within the typical age range for Alzheimer's Disease. There is no direct evidence of BMI, but it is not implausible for a good patient note to miss such information. Therefore, we cannot determine BMI.",
                [],
                "not enough information"
            ],
            "2": [
                "The patient has progressive memory loss, which indicates a gradual and progressive change in memory function. The duration of symptoms is not explicitly stated, but the description of 'progressive memory loss' implies a duration of at least several months.",
                [],
                "included"
            ],
            "3": [
                "There is no mention of the MMSE score in the patient note. It is not implausible for a good patient note to miss such a specific detail.",
                [],
                "not enough information"
            ],
            "4": [
                "There is no mention of the CDR global score or the memory box score in the patient note. It is not implausible for a good patient note to miss such specific details.",
                [],
                "not enough information"
            ],
            "5": [
                "There is no mention of flortaucipir F18 PET scan results in the patient note. It is not implausible for a good patient note to miss such a specific detail.",
                [],
                "not enough information"
            ],
            "6": [
                "The patient's gender is male, but there is no information about contraceptive requirements. There is no information about women's childbearing potential. It is not implausible for a good patient note to miss such specific details.",
                [],
                "not enough information"
            ],
            "7": [
                "There is no mention of the number of study partners or the time spent with them in the patient note. It is not implausible for a good patient note to miss such specific details.",
                [],
                "not enough information"
            ]
        },
        "inclusion_criteria": [
            "1. Have a body mass index (BMI) within the range 18 (17 for Japan participants) to 40 kilograms per square meter (kg/m\u00b2), inclusive, at screening.",
            "2. Have gradual and progressive change in memory function for greater than or equal to (\u2265) 6 months as reported by the participant or informant.",
            "3. Have a mini mental state examination (MMSE) score of 18 to 30 at screening.",
            "4. Have a clinical dementia rating (CDR) global score of 0.5 to 1.0, with a memory box score \u2265 0.5 at screening.",
            "5. Meet flortaucipir F18 positron emission tomography (PET) criteria, as defined in the TAUVID\u2122 FDA label (TAUVID\u2122 prescribing information, 2024), demonstrating evidence of tau pathology.",
            "6. Males who agree to follow contraceptive requirements, or women not of childbearing potential (WNOCBP).",
            "7. Participants must have up to 2 study partners who are with contact with the participant at least 10 hours per week and one of whom can attend study appointments."
        ],
        "exclusion": {
            "1": [
                "The patient does not have any mentioned serious or unstable illnesses other than Alzheimer's Disease, which is included in the study. Therefore, the criterion is not applicable.",
                [],
                "not applicable"
            ],
            "2": [
                "There is no mention of sensitivity to flortaucipir F18 in the patient note.",
                [],
                "not applicable"
            ],
            "3": [
                "There is no mention of contraindication to MRI, including metal implants or claustrophobia in the patient note.",
                [],
                "not excluded"
            ],
            "4": [
                "There is no mention of current exposure to amyloid targeted therapy (ATT) in the patient note.",
                [],
                "not excluded"
            ],
            "5": [
                "There is no mention of previous exposure to any Investigational Medicinal Product administered intrathecal (IT) or any anti-tau therapy in the patient note.",
                [],
                "not excluded"
            ],
            "6": [
                "There is no mention of a history of clinically significant back pain, back pathology, or back injury in the patient note.",
                [],
                "not excluded"
            ]
        },
        "exclusion_criteria": [
            "1. Has current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterological, respiratory, endocrinologic, neurologic (other than Alzheimer's Disease), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with the analyses in this study; or has a life expectancy of less than (\\<)24 months.",
            "2. Have a sensitivity to flortaucipir F18.",
            "3. Have contraindication to magnetic resonance imaging (MRI), including claustrophobia or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemaker.",
            "4. Have a current exposure to an amyloid targeted therapy (ATT). Prior exposure to ATTs greater than 1 year from the last dose may be permitted at the discretion of the investigator and in consultation with the sponsor.",
            "5. Have previous exposure to any Investigational Medicinal Product administered intrathecal (IT) or previous exposure to any anti-tau therapy.",
            "6. Have a history of clinically significant back pain, back pathology and/or back injury (for example, degenerative disease, spinal deformity or spinal surgery) that may predispose to complications or technical difficulty with lumbar puncture."
        ]
    },
    "NCT06413706": {
        "inclusion": {
            "1": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "2": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "3": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "4": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "5": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "6": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "7": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "8": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "9": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "10": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "11": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "12": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "13": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "14": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "15": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "16": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "17": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "18": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "19": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "20": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "21": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "22": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "23": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "24": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "25": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "26": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "27": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ],
            "28": [
                "The criterion is not applicable as the patient is an adult male with a diagnosis not related to high-grade glioma, rather a condition with cerebral atrophy and memory loss, likely indicating a different neurological disorder. The patient note does not mention any high-grade glioma diagnosis.",
                [],
                "not applicable"
            ]
        },
        "inclusion_criteria": [
            "1. Biopsy proven high-grade glioma (HGG) as defined by 2016 World Health Organization (WHO) Classification Criteria, Grade 3-4 including:",
            "2. Anaplastic oligodendroglioma.",
            "3. Anaplastic pleomorphic xanthoastrocytoma,",
            "4. OR as defined by the 2021 WHO Classification Criteria as molecularly characterized:",
            "5. Non-pontine diffuse midline glioma, H3 K27-altered,",
            "6. Diffuse hemispheric glioma, H3 G34-mutant",
            "7. Diffuse pediatric HGG, H3/IDH-wildtype",
            "8. Infant-type hemispheric glioma",
            "9. High-grade astrocytoma with piloid features",
            "10. High-grade pleomorphic xanthoastrocytoma",
            "11. IDH-mutant diffuse glioma with homozygous cyclin- dependent kinase inhibitor 2A/B (CDKN2A/B) deletion,",
            "12. IDH-mutant and 1p/19q co-deleted oligodendroglioma",
            "13. IDH-mutant astrocytoma with homozygous CDKN2A/B deletion",
            "14. Contraceptive use should be consistent with local regulations for participants in clinical studies.",
            "15. Radiotherapy initiated within 6 weeks (+1 week) of diagnosis and administered over 6 weeks (\u00b11 week). Participants \\<3 years of age, considered not suitable for radiotherapy may be eligible.",
            "16. Minimum of 4 weeks between completion of radiation and Cycle 1 Day 1 (C1D1).",
            "17. Maximum of 8 weeks between completion of radiation and C1D1. Exceptional circumstances can be discussed with the medical monitor.",
            "18. Acute effects of prior therapies must be Grade \u22641 unless deemed clinically insignificant by the investigator.",
            "19. Adequate hematologic and organ function \u22647 days prior to C1D1",
            "20. Life expectancy of \u22658 weeks and deemed likely to complete at least 1 cycle of treatment.",
            "21. A performance score of \u226560 using:",
            "22. 1. Lansky scale for participants \\<16 years",
            "23. 2. Karnofsky scale for participants \u226516 years",
            "24. Able to swallow and/or have a gastric/nasogastric tube.",
            "25. Any current systemic steroid use dose must be stable or decreasing at least 7 days prior to C1D1.",
            "26. Able and willing to adhere to study procedures, including frequent blood draws and MRI.",
            "27. At least 28 days since any major surgery, laparoscopic procedure, or a significant traumatic injury.",
            "28. Has a body surface area (BSA) of \u22650.2 m2."
        ],
        "exclusion": {
            "2": [
                "The patient note does not mention a diagnosis of DIPG or diffuse midline glioma located in the pons, which are the criteria for exclusion. It is highly unlikely that such a diagnosis would be missed if present, given the severity and specificity of the condition.",
                [],
                "not applicable"
            ],
            "3": [
                "The patient note does not mention any recurrence or progression of the disease during or after radiotherapy, and there is no indication of a high-grade glioma diagnosis.",
                [],
                "not excluded"
            ],
            "4": [
                "The patient note does not mention any history of low-grade glioma or previously treated malignancy that now meets high-grade criteria.",
                [],
                "not applicable"
            ],
            "5": [
                "The patient note does not mention any known pathogenic somatic mutations in ALK, BRAF, or NTRK genes.",
                [],
                "not excluded"
            ],
            "6": [
                "The patient note does not mention any prior HGG treatment other than surgery and radiotherapy (with or without concomitant temozolomide).",
                [],
                "not excluded"
            ],
            "7": [
                "The patient note does not mention current enrollment in another trial.",
                [],
                "not excluded"
            ],
            "8": [
                "The patient note does not mention any treatment with an investigational product within the last 30 days or 5 half-lives.",
                [],
                "not excluded"
            ],
            "9": [
                "The patient note does not mention any prior malignancy within the previous 3 years.",
                [],
                "not excluded"
            ],
            "10": [
                "The patient note does not mention any preexisting medical condition(s) that would preclude study participation.",
                [],
                "not excluded"
            ],
            "11": [
                "The patient note does not mention any serious, active, systemic infection requiring IV antibiotic, antifungal, or antiviral therapy.",
                [],
                "not excluded"
            ],
            "12": [
                "The patient note does not mention any intolerability or hypersensitivity to temozolomide, abemaciclib, their excipients, or dacarbazine.",
                [],
                "not excluded"
            ],
            "13": [
                "The patient note does not mention receiving a live virus vaccine within 28 days of C1D1.",
                [],
                "not excluded"
            ],
            "14": [
                "The patient note does not mention being pregnant, breastfeeding, or intending to become pregnant during the study.",
                [],
                "not excluded"
            ]
        },
        "exclusion_criteria": [
            "1. Participants are excluded if any of the following apply:",
            "2. Diffuse Intrinsic Pontine Glioma (DIPG) or diffuse midline glioma located in the pons.",
            "3. Recurrent or refractory HGG including any recurrence/progression during/after radiotherapy.",
            "4. Secondary HGG, defined as a previously treated low-grade glioma that now meets high- grade criteria, or that resulted from a previously treated malignancy.",
            "5. Have known pathogenic somatic mutations appropriate for an anaplastic lymphoma kinase (ALK), B-rapidly accelerated fibrosarcoma (BRAF), or neurotrophic tyrosine receptor kinase (NTRK ) inhibitor, in regions where these therapies are available and deemed appropriate by the investigator.",
            "6. Prior HGG treatment (including bevacizumab), except for surgery and radiotherapy (with or without concomitant temozolomide).",
            "7. Current enrollment in another trial deemed incompatible with this study.",
            "8. Treatment with an investigational product within the last 30 days or 5 half-lives (whichever is longer).",
            "9. Prior malignancy within the previous 3 years that, per the investigator and the medical monitor, may affect interpretation of study results.",
            "10. A preexisting medical condition(s) that, per the investigator, would preclude study participation.",
            "11. Any serious, active, systemic infection requiring IV antibiotic, antifungal, or antiviral therapy, including acute hepatitis B or C, or Human Immunodeficiency Virus at C1D1.",
            "12. Intolerability or hypersensitivity such as urticaria, anaphylaxis, toxic necrolysis, and/or Stevens-Johnson syndrome to temozolomide, and/or abemaciclib, their excipients, or dacarbazine.",
            "13. Received a live virus vaccine within 28 days of C1D1.",
            "14. Pregnant, breastfeeding, or intend to become pregnant during the study."
        ]
    }
}